MedTrace Logo

ChEmo-Genomics Based Treatment of Acute Myeloid Leukemia

NCT02619071 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 87

Last updated 2016-06-28

No results posted yet for this study

Summary

Adult acute myeloid leukemia (AML) is a heterogeneous hematologic malignancy associated with poor prognosis, especially after relapse. High-throughput genomic studies have highlighted the importance of molecular alteration in the pathophysiology, clinical evolution and treatment response of AML. In addition, identification of specific gene mutation can be targeted by specific inhibitors, opening the way to personalized treatments. However, only a limited number of gene mutations are druggable or actionable, highlighting the need for additional information to guide treatment choices. Among them, new Drug Screening Tests (DST) allow for the screening of library of hundreds of drugs to ex-vivo patient-derived AML cells. Combination of genomic and pharmacologic approaches might therefore improve prediction of drug effects. There is an urgent need to bring these approaches into the clinic but feasibility trials are necessary before incorporating them into treatments strategies.The proposed study is a prospective multicentre feasibility study of a combined "chemo-genomic" approach in patients with advanced AML.

Conditions

  • Leukemia, Myeloid, Acute

Interventions

PROCEDURE

Tumor sampling

Bone marrow aspirate, blood sampling

BIOLOGICAL

Constiutional DNA sampling

Buccal swab or Hair follicles

Sponsors & Collaborators

  • Cancer Research Center of Marseille

    collaborator OTHER

  • Institut Paoli-Calmettes

    lead OTHER

Study Design

Allocation
NA
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-08-31
Primary Completion
2017-08-31
Completion
2017-08-31

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02619071 on ClinicalTrials.gov